Is Rxsight Inc (RXST) overvalued? · rev $139.9M
Rxsight Inc (RXST) is a medical devices company listed on NASDAQ.
This page asks whether Rxsight Inc (RXST) looks expensive on cached numbers — not a short thesis.
Latest reported RXST revenue for 2024-12-31 was $139.9M. Net income was -$27.5M. Revenue was up 57.1% from 2023-12-31 to 2024-12-31. RXST currently screens at market cap $198.3M.
RXST currently screens at market cap $198.3M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next RXST 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the RXST stock page for the full model, not this heading.
Not investment advice.